Australia markets open in 4 hours 44 minutes

EHAVE, Inc. (EHVVF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0090+0.0001 (+1.12%)
At close: 03:43PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.0089
Open0.0090
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0075 - 0.0090
52-week range0.0055 - 0.4719
Volume1,159,349
Avg. volume1,934,171
Market cap905,651
Beta (5Y monthly)2.38
PE ratio (TTM)N/A
EPS (TTM)-0.1100
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    2021 Psychedelic Investor Guide Released

    MIAMI, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today its wholly owned KetaDASH will be one of the sponsors of the 2021 Psychedelic Investor Guide. KetaDASH is an Intravenous (IV) based, home delivery platform for patients who have been prescribed Ketamine. “Sponsoring the Psychedelic Investor Guide is a great opportunity for Ehave as we roll out our KetaDASH platf

  • GlobeNewswire

    Ehave Hires Contract Research Organization To Conduct Ketamine Clinical Trial In Miami, Florida

    Ehave one of the first companies to pioneer the collection of certain data points, as well as to seek to understand how ketamine can potentially resolve issues in the brain through a process called neuroplasticityMIAMI, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has hired KGK Science Inc., a contract research organization (CRO) that is wholly-owned by Ketamin

  • GlobeNewswire

    Psychedelic Stock Review Initiates Coverage on Ehave Inc.

    MIAMI, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today the Psychedelic Stock Review has initiated coverage. “Ehave is about to release a number of digital information tools and services made to enhance the effectiveness and practicality of Psychedelic treatments, for both patients and the medical community,” stated Roland Rick Perry, editor of the